Activest Wealth Management
RARE icon

Activest Wealth Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Activest Wealth Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1
Closed -$33 – 1301
2026
Q2 		$33 Hold
1
– – ﹤0.01% 1306
2026
Q1 		$21 Sell
1
-37
-97% -$833 ﹤0.01% 1208
2025
Q4 		$874 Buy
38
+37
+3,700% +$1.22K ﹤0.01% 958
2025
Q3 		$30 Sell
1
-7
-88% -$210 ﹤0.01% 1108
2025
Q2 		$291 Buy
+8
New +$288 ﹤0.01% 938
2025
Q1 		– Sell
-1
Closed -$42 – 1151
2024
Q4 		$42 Buy
+1
New +$50 ﹤0.01% 767

Other funds holding RARE

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Activest Wealth Management's RARE Position: Q3 2026 in Review

Activest Wealth Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2026, closing a stake of 1 share — an estimated $33 sold.

Activest Wealth Management first reported a position in RARE in Q4 2024 and held it in 6 quarters. The position peaked at $874 in Q4 2025. 85 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • Activest Wealth Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Activest Wealth Management sold 1 Ultragenyx Pharmaceutical share in Q3 2026, an estimated $33.
  • Activest Wealth Management first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and held it in 6 quarters.
  • Activest Wealth Management's Ultragenyx Pharmaceutical position peaked at $874 in Q4 2025.
  • 85 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on Activest Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.